文献速递血栓与止血

rIX-FP延长给药间隔至21天在成人/青少年血友病B患者中的长期安全性和有效性

Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.
PubMed 文献 · J Thromb Haemost · 2020-03-30

这项国际多中心扩展研究评估了rIX-FP(重组凝血因子IX与重组人白蛋白融合蛋白)在血友病B(FIX≤2%)既往接受治疗患者中的长期预防治疗。59例患者(13-63岁)接受7、10、14天方案,部分可切换至21天方案(100 IU/kg);各方案年化自发性出血率低,96.5%的出血事件经1-2次输注成功治疗,无患者产生抑制物。

要点

  • rIX-FP 21天预防方案在经选择的成人患者中可行,可减少治疗负担
  • 各给药间隔年化自发性出血率低,14天与21天方案疗效与7天方案相当
  • 96.5%出血事件经1-2次rIX-FP输注成功治疗,无抑制物产生

核心结论

  • rIX-FP延长间隔预防治疗提供给药灵活性,在经选择的患者中21天方案可作为减少治疗负担和个体化治疗的替代选择。

研究设计与样本

  • 国际多中心扩展研究,纳入既往III期研究或术后启动rIX-FP预防治疗的血友病B(FIX≤2%)患者。
  • 共59例男性既往接受治疗患者(PTPs),年龄13-63岁。
  • 7天方案35-50 IU/kg,10天或14天方案50-75 IU/kg;≥18岁且14天方案稳定控制≥6个月者可切换至21天方案100 IU/kg。

主要发现

  • 符合21天方案条件的患者单次100 IU/kg rIX-FP后平均终末半衰期为143.2小时。
  • 平均稳态FIX谷浓度从7天方案的22%降至21天方案的7.6%。
  • 7、10、14、21天方案的中位(Q1,Q3)年化自发性出血率分别为0.00(0.00,1.67)、0.28(0.00,1.10)、0.37(0.00,1.68)、0.00(0.00,0.45)。
  • 14天与21天方案疗效与7天方案相当;96.5%出血事件经1-2次rIX-FP输注成功治疗。
  • 无患者产生抑制物,治疗耐受性良好。

关键数值与推荐

  • 21天方案适用条件:年龄≥18岁且14天方案稳定控制≥6个月,剂量100 IU/kg。
  • 单次100 IU/kg后平均终末半衰期143.2小时;平均稳态谷浓度7天方案22%、21天方案7.6%。
  • 年化自发性出血率中位数:7天0.00、10天0.28、14天0.37、21天0.00。
  • 96.5%出血事件经1-2次输注成功治疗。

临床怎么用

  • 对血友病B成人患者可依据出血控制情况个体化延长rIX-FP给药间隔至14天或21天。
  • 21天方案可作为经选择患者的替代选择,以减少治疗负担。

局限性

  • 21天方案仅适用于≥18岁且14天方案稳定控制≥6个月的患者,非全部人群。
  • 研究为单臂扩展研究,未设随机对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An international, multicenter extension study evaluated recombinant fusion protein linking recombinant coagulation factor IX (FIX) with recombinant human albumin (rIX-FP) in hemophilia B (FIX ≤ 2%) patients previously enrolled in a phase III study or who initiated rIX-FP prophylaxis following surgery. OBJECTIVES: To investigate the long-term safety and efficacy of rIX-FP prophylaxis in adult previously treated patients (PTPs) with hemophilia B. METHODS: Male PTPs were treated with a 7- (35-50 IU/kg), 10- or 14-day regimen (50-75 IU/kg). Patients ≥18 years who were well-controlled on a 14-day regimen for ≥6 months could switch to a 21-day regimen (100 IU/kg). RESULTS: A total of 59 patients (aged 13-63 years) participated in the study. Following a single dose of 100 IU/kg rIX-FP, in patients eligible for the 21-day regimen, the mean terminal half-life was 143.2 hours. Mean steady-state FIX trough activity levels ranged from 22% with the 7-day regimen to 7.6% with the 21-day regimen. Median (Q1, Q3) annualized spontaneous bleeding rates were 0.00 (0.00, 1.67), 0.28 (0.00, 1.10), 0.37 (0.00, 1.68), and 0.00 (0.00, 0.45) for the 7-, 10-, 14-, and 21-day regimens, respectively. Comparable efficacy was demonstrated for both the 14- and 21-day regimens compared to the 7-day regimen. Overall, 96.5% of bleeding episodes were treated successfully with 1 to 2 rIX-FP infusions. No patients developed an inhibitor and treatment was well tolerated. CONCLUSIONS: rIX-FP extended interval prophylaxis provides dosing flexibility and, in selected patients, a 21-day regimen may provide an alternative option to minimize treatment burden and individualize treatment.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020. PMID: 32078256. doi:10.1111/jth.14778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。